These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 22935449)

  • 1. Metabolomics and its potential in drug development.
    Beyoğlu D; Idle JR
    Biochem Pharmacol; 2013 Jan; 85(1):12-20. PubMed ID: 22935449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolomics in toxicology: preclinical and clinical applications.
    Robertson DG; Watkins PB; Reily MD
    Toxicol Sci; 2011 Mar; 120 Suppl 1():S146-70. PubMed ID: 21127352
    [No Abstract]   [Full Text] [Related]  

  • 3. The quest for biomarkers in tuberculosis.
    Parida SK; Kaufmann SH
    Drug Discov Today; 2010 Feb; 15(3-4):148-57. PubMed ID: 19854295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of metabolomics in drug discovery and development.
    Wishart DS
    Drugs R D; 2008; 9(5):307-22. PubMed ID: 18721000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of metabolomics in preclinical and clinical drug development.
    Kumar B; Prakash A; Ruhela RK; Medhi B
    Pharmacol Rep; 2014 Dec; 66(6):956-63. PubMed ID: 25443721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolomics for early detection of drug-induced kidney injury: review of the current status.
    Boudonck KJ; Rose DJ; Karoly ED; Lee DP; Lawton KA; Lapinskas PJ
    Bioanalysis; 2009 Dec; 1(9):1645-63. PubMed ID: 21083109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolomics in drug discovery and development.
    Robertson DG; Frevert U
    Clin Pharmacol Ther; 2013 Nov; 94(5):559-61. PubMed ID: 24145714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers in clinical drug development.
    Gobburu JV
    Clin Pharmacol Ther; 2009 Jul; 86(1):26-7. PubMed ID: 19536121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promises of biomarkers in drug development--a reality check.
    Marrer E; Dieterle F
    Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of metabolomics biomarkers for early detection of nephrotoxicity.
    Boudonck KJ; Mitchell MW; Német L; Keresztes L; Nyska A; Shinar D; Rosenstock M
    Toxicol Pathol; 2009 Apr; 37(3):280-92. PubMed ID: 19380839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The discovery process in the pharmaceutical industry].
    Scatton B
    J Soc Biol; 2009; 203(3):249-69. PubMed ID: 19833071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker discovery in biological specimens (plasma, hair, liver and kidney) of diabetic mice based upon metabolite profiling using ultra-performance liquid chromatography with electrospray ionization time-of-flight mass spectrometry.
    Tsutsui H; Maeda T; Min JZ; Inagaki S; Higashi T; Kagawa Y; Toyo'oka T
    Clin Chim Acta; 2011 May; 412(11-12):861-72. PubMed ID: 21185819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are meaningful predictions of toxicological outcomes in clinical trials based on in vitro diagnostics of preclinical drug candidates possible?
    Kroll F; Dreger M
    Future Med Chem; 2010 Nov; 2(11):1613-7. PubMed ID: 21428831
    [No Abstract]   [Full Text] [Related]  

  • 15. Metabolomics for bioactivity assessment of natural products.
    Yuliana ND; Khatib A; Choi YH; Verpoorte R
    Phytother Res; 2011 Feb; 25(2):157-69. PubMed ID: 20658470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety biomarkers in preclinical development: translational potential.
    Sasseville VG; Mansfield KG; Brees DJ
    Vet Pathol; 2014 Jan; 51(1):281-91. PubMed ID: 24091814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prototypical process for creating evidentiary standards for biomarkers and diagnostics.
    Altar CA; Amakye D; Bounos D; Bloom J; Clack G; Dean R; Devanarayan V; Fu D; Furlong S; Hinman L; Girman C; Lathia C; Lesko L; Madani S; Mayne J; Meyer J; Raunig D; Sager P; Williams SA; Wong P; Zerba K
    Clin Pharmacol Ther; 2008 Feb; 83(2):368-71. PubMed ID: 18091762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic profiling as a tool for understanding mechanisms of toxicity.
    Clarke CJ; Haselden JN
    Toxicol Pathol; 2008 Jan; 36(1):140-7. PubMed ID: 18337232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical analytical approach for the identification of biomarker candidates in prediabetic state based upon metabonomic study by ultraperformance liquid chromatography coupled to electrospray ionization time-of-flight mass spectrometry.
    Tsutsui H; Maeda T; Toyo'oka T; Min JZ; Inagaki S; Higashi T; Kagawa Y
    J Proteome Res; 2010 Aug; 9(8):3912-22. PubMed ID: 20557141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolomics in pharmaceutical research and development: metabolites, mechanisms and pathways.
    Xu EY; Schaefer WH; Xu Q
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):40-52. PubMed ID: 19152212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.